Clinical trial
Vaccine Therapy in Treating Patients With Resected or Locally Advanced…
NCT00008099 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00008099 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer |
| Official title | Phase I Dose Escalation Trial of a 100 aa Synthetic Mucin Peptide Admixed With SB-AS2 as Adjuvant in Locally Advanced and Resected Pancreatic Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | MUC1 antigen/SB AS-2 |
| Enrollment | 25 |
| Start date | May 1, 1998 |
| Primary completion | Mar 1, 2001 |
| Completion | Feb 1, 2004 |
| First posted | May 4, 2004 |
| Last update posted | Jan 20, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: